References
- Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303–319.
- Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547–561.
- Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401–1413.
- Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017;17:1358–1369.
- Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant. 2013;27:217–226.
- Shihab F, Qazi Y, Mulgaonkar S, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant. 2017;17:2363–2371.
- Cooper M, Wiseman AC, Zibari G, et al. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials. Clin Transplant. 2013;27:E625–E635.
- Ueno P, Felipe C, Ferreira A, et al. Wound healing complications in kidney transplant recipients receiving everolimus. Transplantation. 2017;101:844–850.
- Pascual J, Srinivas TR, Chadban S, et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access J Clin Trials. 2014;6:45–54.
- Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29:1979–1991.
- Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019;103:1953–1963.
- Berger SP, Sommerer C, Witzke O, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from TRANSFORM study. Am J Transplant. 2019;19:3018–3034.
- Sommerer C, Suwelack B, Dragun D, et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;96:231–244.
- Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation. 2009;88:69–76.
- Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transplant Int. 2010;23:1084–1093. Erratum in: Transpl Int. 2012;25:138.
- Manzia TM, Carmellini M, Todeschini P, et al. A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs. delayed) introduction of everolimus in de novo kidney transplant recipients, with a follow-up evaluation at 12 month after transplant (NEVERWOUND study). Transplantation. 2020;104:374–386.
- Cibrik D, Silva HT Jr, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013;95:933–942.
- Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77:1555–1561.
- Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant. 2007;21:460–465.
- Grim SA, Slover CM, Sankary H, et al. Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant Proc. 2006;38:3520–3523.
- Zuckermann A, Barten MJ. Surgical wound complications after heart transplantation. Transpl Int. 2011;24:627–636.
- Koch M, Kantas A, Ramcke K, et al. Surgical complications after kidney transplantation: different impacts of immunosuppression, graft function, patient variables, and surgical performance. Clin Transplant. 2015;29:252–260.